|Home | About | Journals | Submit | Contact Us | Français|
Cytokines such as IL1 are central mediators of joint inflammation in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and polymorphism in IL1 has been associated with disease susceptibility and severity.
To evaluate the role of the polymorphism rs1143634 in the IL1B gene in the pharmacogenetic of RA and AS patients treated with infliximab.
IL1B genotyping was performed in a subset of 42 RA and 39 AS patients treated with infliximab. Response was assessed at the 3rd and 6th month of treatment by EULAR for RA and BASDAI criteria for AS.
According to the EULAR criteria no significant associations were found between IL1B genotypes and response in RA patients. Distribution of IL1B rs1143634 genotype revealed a significant association in AS between the T allele with better response (responders: T 93.5%, C 60.4% vs. non responders: T 6.7%, C 39.6%; p=0.007) and between TT+TC genotypes and better response (CC 52.4% vs. 92.3% TT+TC; p=0.009) at 3 months after treatment commencement according to BASDAI criteria.
rs1143634 seems to influence the response to infliximab treatment in AS but not in AR patients though this finding must be confirmed in a study with larger sample size.